ABIVAX Société Anonyme (ABVX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with ABVX?
Powered by Yahoo ScoutAbivax is moving from late-stage clinical development toward potential commercialization of obefazimod for ulcerative colitis. Recent coverage points to improved safety data, completed Phase 3 maintenance results, expanded funding, and a planned U.S. regulatory filing by year-end 2026. Execution, cash usage, manufacturing readiness, and regulatory approval remain central risks.
- Previous Close
89.06 - Open
87.66 - Bid 121.16 x 100
- Ask 119.33 x 100
- Day's Range
85.81 - 88.90 - 52 Week Range
69.81 - 148.83 - Volume
842,193 - Avg. Volume
1,096,375 - Market Cap (intraday)
7.58B - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-6.08 - Earnings Date Sep 21, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
163.58 - Zacks Rating Bearish
Recent News
View MorePerformance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (current)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-62.88%
-
Return on Equity (ttm)
-252.35%
-
Revenue (ttm)
4.67M
-
Net Income Avi to Common (ttm)
-401.22M
-
Diluted EPS (ttm)
-6.08
Balance Sheet and Cash Flow
-
Total Cash (mrq)
402.38M
-
Total Debt/Equity (mrq)
0.33%
-
Levered Free Cash Flow (ttm)
-125.9M
